Fluent BioSciences v3.0 Kits Now Shipping with Nuclei Compatibility

News

Fluent BioSciences launches industry’s most accessible, cost-effective and scalable technology (PIPseq™) to accelerate adoption of single-cell RNA sequencing in any laboratory

Priced as low as $300 per reaction, the T2 and T20 kits enable any researcher to immediately access the power of single-cell transcriptomics with no capital investment WATERTOWN, Mass., June 23, 2022 /PRNewswire/ — Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, announced the launch of two new breakthrough products for […]

Read More

Fluent BioSciences and NanoCellect announce joint collaboration to improve resolution of single-cell RNA sequencing analysis of rare cell populations

Watertown, MA, June 17, 2022 – Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, and NanoCellect Biomedical, Inc., a leader in the development and manufacturing of innovative and affordable solutions for cell sorting, jointly announced a collaboration to improve resolution and efficiency of single-cell RNA sequencing (scRNA-seq) […]

Read More

Fluent BioSciences expands access to industry’s most flexible and scalable technology (PIPseq) to enable sensitive single-cell transcriptome analysis in any laboratory

Watertown, MA., May 5, 2022 – Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, announced expanded early access to two new products for 3′ single-cell RNA analysis. Scaled to efficiently and effectively meet diverse experimental demands, PIPseqTM T2 and T20 kits capture up to 2,000 and 20,000 […]

Read More

Fluent BioSciences awarded $1.7 Million SBIR grant to commercialize PIPseq™ a breakthrough platform technology enabling scalable, sensitive single-cell analysis in any laboratory

Funding will be used to support commercialization of single-cell RNA sequencing (scRNA-Seq) products and services to address the critical need for accessibility, affordability and scalability. Watertown, MA., March 9, 2022 – Fluent BioSciences, a biotechnology company focused on making single-cell analysis simple and accessible to every researcher, announced today that it has been awarded a […]

Read More

Meet Fluent BioSciences at the ASHG Virtual Meeting (Oct 18-22, 2021)

Fluent BioSciences will be attending the American Society of Human Genetics (ASHG) virtual meeting and presenting three posters showcasing our technology and single cell RNA sequencing applications data from early customers. Attend to learn more about our technology and upcoming products.

Read More